240 related articles for article (PubMed ID: 25065489)
1. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
Nielsen S; Hillhouse M; Mooney L; Ang A; Ling W
J Subst Abuse Treat; 2015 Jan; 48(1):70-6. PubMed ID: 25065489
[TBL] [Abstract][Full Text] [Related]
2. Cognitive Behavioral Therapy Improves Treatment Outcomes for Prescription Opioid Users in Primary Care Buprenorphine Treatment.
Moore BA; Fiellin DA; Cutter CJ; Buono FD; Barry DT; Fiellin LE; O'Connor PG; Schottenfeld RS
J Subst Abuse Treat; 2016 Dec; 71():54-57. PubMed ID: 27776678
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
[TBL] [Abstract][Full Text] [Related]
4. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
[TBL] [Abstract][Full Text] [Related]
5. Comparing buprenorphine induction experience with heroin and prescription opioid users.
Nielsen S; Hillhouse M; Mooney L; Fahey J; Ling W
J Subst Abuse Treat; 2012 Oct; 43(3):285-90. PubMed ID: 22301084
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
[TBL] [Abstract][Full Text] [Related]
7. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.
Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W
J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
[TBL] [Abstract][Full Text] [Related]
9. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.
D'Amore A; Romano F; Biancolillo V; Lauro G; Armenante C; Pizzirusso A; Del Tufo S; Ruoppolo C; Auriemma F; Cassese F; Oliva P; Amato P
Clin Drug Investig; 2012 Jul; 32(7):427-32. PubMed ID: 22559256
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
12. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
[TBL] [Abstract][Full Text] [Related]
13. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
McKeganey N; Russell C; Cockayne L
J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
[TBL] [Abstract][Full Text] [Related]
14. Engagement, retention, and abstinence for three types of opioid users in Florida.
McCabe BE; Santisteban DA; Mena MP; Duchene DM; McLean C; Monroe M
Subst Use Misuse; 2013 Jun; 48(8):623-34. PubMed ID: 23750774
[TBL] [Abstract][Full Text] [Related]
15. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
[TBL] [Abstract][Full Text] [Related]
16. The Prescription Opioid Addiction Treatment Study: What have we learned.
Weiss RD; Rao V
Drug Alcohol Depend; 2017 Apr; 173 Suppl 1(Suppl 1):S48-S54. PubMed ID: 28363320
[TBL] [Abstract][Full Text] [Related]
17. Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.
Meyer AC; Miller ME; Sigmon SC
Addict Behav; 2015 Mar; 42():189-93. PubMed ID: 25481453
[TBL] [Abstract][Full Text] [Related]
18. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
[TBL] [Abstract][Full Text] [Related]
19. Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.
Wakeman SE; Chang Y; Regan S; Yu L; Flood J; Metlay J; Rigotti N
J Addict Med; 2019; 13(4):253-257. PubMed ID: 30550392
[TBL] [Abstract][Full Text] [Related]
20. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.
Moore BA; Fiellin DA; Barry DT; Sullivan LE; Chawarski MC; O'Connor PG; Schottenfeld RS
J Gen Intern Med; 2007 Apr; 22(4):527-30. PubMed ID: 17372805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
